Table 1 Presentation characteristics of SJIA versus NB patients

Age (years)

7.2 ± 4.7

3.0 ± 3.5

<0.0001

Gender

Famle 51%

Female 42%

0.26

Male 49%

Male 58%

Race

White 91%

White 85%

0.86

Black 6%

Black 7%

Hispanic 3%

Hispanic 3%

Other 5%

Fever present (0=no, 1=yes)

45/45 (100%)

12/71 (18%)

<0.0001

Time to diagnosis (months)

1.5 (65)

1.2 (78)

0.18

Arthritis

51/65 (78%)

1/71 (1%)

<0.0001

Rash

53/64 (83%)

2/71 (3%)

<0.0001

Abdominal mass

1/65 (2%)

29/71 (41%)

0.0001

Weight loss

11/65 (17%)

5/71 (7%)

0.07

Gait disturbance or extremity pain

45/65 (41%)

13/73 (18%)

<0.0001

Neuroblastoma stage

n/a

Stage 1 = 19/62 (31%)

n/a

Stage 2 = 3/62 (5%)

Stage 3 = 9/62(14%)

Stage 4 =31/62 (50%)

LDH (units/L)

637 ± 530 (35)

1842 ± 2410 (46)

0.005

Uric Acid (mg/dL)

3.3 ± 1.2 (22)

5.1 ± 2.9 (34)

0.005

Crp (mg/dL)

14.9 ± 25.3 (26)

10.2 ± 7.2 (4)

0.71

ESR (mm/hr)

81.6 ± 36.3 (58)

61.7 ± 46.0 (13)

0.09

PLT count

464,016 ± 173,148 (62)

327,419 ± 136,488 (62)

<0.00001

WBC

18,881 ± 11,449 (63)

10,484 ± 5,892 (68)

<0.00001

HGB (g.dL)

10.2 ± 1.80 (62)

10.3 ± 2.46 (67)

0.97

Neurtophil %

73 ± 14 (57)

0.49 ± 0.17 (64)

<0.00001

Lymphocyte %

17 ± 10 (47)

40 ± 17 (64)

<0.00001

Ferntin (ng/mL)

4,016 ± 6, 135 (50)

159 ± 205 (29)

0.001

D-Dimer elevated

34/36 (94%)

2/2 (100%)

0.73

Aldolase

15.6 ± 11.4 (28)

8.85 ± 1.01 (2)

0.42